RxDoctor Payments Data

Paul Lawrence, MD

Internal Medicine · Chattanooga, TNNPI 1376630707

Payments from drug & device makers

$3,235in general payments, 2019–2025

Across 191 payments — averaging $16.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$486
  • AstraZeneca$420
  • Pfizer$327
  • AbbVie$235
  • Amgen$217
  • Boehringer Ingelheim$191
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$3,235100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,235 in reported general payments places this provider in the 80th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$98,223
Medicare patients
218
Services billed
5,668

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide72$105,083
JardianceEmpagliflozin60$83,697
TrulicityDulaglutide32$72,060
XareltoRivaroxaban43$41,649
EliquisApixaban26$39,642
FarxigaDapagliflozin Propanediol36$36,637
JanuviaSitagliptin Phosphate23$23,319
Janumet XrSitagliptin Phos/Metformin Hcl17$15,771
Breo ElliptaFluticasone/Vilanterol28$15,585
Lagevrio (Eua)Molnupiravir22$14,375
Pravastatin Sodium378$8,029
Irbesartan169$7,577
Fluticasone-SalmeterolFluticasone Propion/Salmeterol28$7,323
Rosuvastatin Calcium458$7,104
Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl19$4,686

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$486$105,08372 claims
Boehringer IngelheimJardiance$191$83,69760 claims
Lilly USA, LLCTrulicity$111$72,06032 claims
MerckJanuvia, Janumet Xr, Lagevrio (Eua)$95$53,46562 claims
Johnson & JohnsonXarelto$137$41,64943 claims
PfizerEliquis$327$39,64226 claims
AstraZenecaFarxiga$420$36,63736 claims
GSKBreo Ellipta$44$15,58528 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →